ClinicalTrials.Veeva

Menu

Imaging the Pathogenesis of Cerebral Small Vessel Disease

Johns Hopkins University logo

Johns Hopkins University

Status

Enrolling

Conditions

Hypertension
Ischemic Stroke
Diabetes
Hyperlipidemias

Study type

Observational

Funder types

Other
NIH

Identifiers

NCT05703386
IRB00313202

Details and patient eligibility

About

Cerebral small vessel disease (CSVD) can lead to vascular cognitive impairment and dementia (VCID). The hallmark of CSVD is the appearance and progression of white matter hyperintensities (WMH) on MRI. The goal of this study it to recruit and follow individuals at risk for WMH progression and use serial MRI scanning to gain insights into the pathogenesis of CSVD.

Full description

Vascular Cognitive Impairment and Dementia (VCID) which is attributed in large part to cerebral small vessel disease (CSVD) is prevalent in patients with a history of stroke and vascular risk factors. The hallmark of CSVD is white matter hyperintensities (WMH) seen on T2-weighted MRI. The initial amount, and rate of progression, of WMH is tied closely with the development and progression cognitive deficits. It is hypothesized that one of the early pathologic features in the normal appearing white matter (NAWM), before it progresses to WMH is disruption of the blood-brain barrier (BBB) and loss of micro-structural integrity. The purpose of this study is track the progression of WMH using multiple MRI biomarkers looking at BBB disruption (DCE, DSC, ASL), micro-structural changes (multi-shell DTI), and macrostructural changes (FLAIR, SWI, T1) to better understand the pathogenesis of CSVD. Patients with a history of a stroke, at least one vascular risk factor, and evidence of CSVD on MRI may be eligible for this study. We will follow 50 patients with 3 MRIs performed over 1.25 years

Enrollment

50 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Clinical or radiographic evidence of ischemic stroke
  • One vascular risk factor (hypertension, hyperlipidemia, or diabetes)
  • Evidence of cerebral small vessel disease on MRI

Exclusion criteria

  • Inability to complete 3 research MRI scans over 1.25 years

Trial contacts and locations

1

Loading...

Central trial contact

Sera Chase

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems